Knowledge Center
Angew. Chem.∣A Novel Targeted Delivery Strategy for the CRISPR/Cas9 System
Release date:2026-03-13
This study has developed a novel strategy based on bioorthogonal reactions to achieve targeted enrichment of the CRISPR/Cas9 system at tumor sites, thereby enabling dual-targeted cancer immunotherapy. The researchers found that a tumor microenvironment–degradable hollow manganese dioxide (H-MnO2) nanoplatform can simultaneously enable selective in vivo labeling of tumor sites and activation of the cGAS-STING pathway. Subsequently, lipid nanoparticles loaded with the CRISPR/Cas9 system accumulate in tumor tissues via bioorthogonal reactions and, by knocking down the protein tyrosine phosphatase N2 gene, further enhance the sensitivity of tumors to immunotherapy. In summary, this study provides a modular platform for precise in vivo gene editing and, by reshaping the tumor immune microenvironment, elicits robust antitumor responses, thereby offering strong support for the translational application of CRISPR technology in cancer immunotherapy.
Previous page:
Goonie Biotechnology (Guangzhou) Co., Ltd.
Room 321–332, Building G5, No. 39 Ruihe Road, Huangpu District, Guangzhou
Customer Service QR Code
Friendly Links
